雷替曲塞经TACE治疗原发性巨块型肝癌的临床疗效评价

发布时间：2018-03-26 11:38

本文选题：原发性肝癌　切入点：巨块型肝癌　出处：《临床放射学杂志》2017年08期

【摘要】：目的评价雷替曲塞经TACE治疗原发性巨块型肝癌的临床疗效。方法回顾性分析2013年7月至2015年8月本院TACE治疗原发性巨块型肝癌患者56例临床资料,根据术中化疗方案分为两组:5-FU组(A组)24例,雷替曲塞组(B组)32例。比较两组术后临床疗效、不良反应及生存期。结果临床疗效A组有效率(RR)29.2%、疾病控制率(DCR)75.0%,B组37.5%、78.1%,两组比较均无统计学差异(P0.05);不良反应A组与B组比较无统计学差异(P0.05);A组平均生存期及中位生存期为9.86个月、8.80个月,B组为12.78个月、13.70个月,B组平均生存期及中位生存期均明显大于A组,差异具有统计学意义(P0.05)。结论雷替曲塞用于TACE治疗原发性巨块型肝癌的临床疗效及不良反应与5-FU相当,但雷替曲塞能显著延长患者生存期。
[Abstract]:Objective to evaluate the clinical efficacy of retitrexed TACE in the treatment of primary giant hepatocellular carcinoma (PHC). Methods 56 patients with PHC treated by TACE from July 2013 to August 2015 were retrospectively analyzed. According to the intraoperative chemotherapy regimen, the patients were divided into two groups: group A (n = 24), group A (n = 24) and group B (n = 32). Results the effective rate and disease control rate of group A were 75.0% and 78.5%, respectively. There was no significant difference between the two groups (P 0.05), and there was no significant difference between group A and group B in mean survival and median survival (P 0.05A). The mean survival and median survival of group B were significantly higher than those of group A at 8.80 months, and the mean survival and median survival of group B at 13.70 months were significantly higher than those of group A, and the mean survival time of group B was 9.86 months, and that of group B was 12.78 months. Conclusion the clinical efficacy and side effects of letitrexed in the treatment of primary giant hepatocellular carcinoma are similar to those of 5-FU, but the survival time of patients can be significantly prolonged by letitrexed.
【作者单位】：咸宁市中心医院湖北科技学院附属第一医院放射科介入中心;
【分类号】：R735.7

【参考文献】